Back to Journals » Clinical Ophthalmology » Volume 4

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results

Authors Schmier J, Covert DW

Published 6 May 2010 Volume 2010:4 Pages 437—445


Review by Single-blind

Peer reviewer comments 2

Jordana K Schmier1, David W Covert2

1Managing Scientist, Exponent Inc., Alexandria, VA, USA; 2Associate Director, Health Economics, Alcon Research Ltd., Ft. Worth, TX, USA

Objective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population.

Research design and methods: A model was developed to estimate first-year medical costs. Model inputs were based on weighted results from three previous studies. Treatment patterns were derived from a claims database analysis. Published studies were used to estimate visit-related resource use. Costs were obtained from standard sources.

Results: Across studies, 27,809 patients met study criteria, 44.2% of whom remained on their index therapy for 12 months. Adjunctive therapy was needed in 22.5%, 18.5%, and 11.9% of bimatoprost, latanoprost, and benzalkonium chloride (BAK)-free travoprost patients, respectively. Median days to initiating adjunctive therapy were 64, 67, and 127 for bimatoprost, latanoprost, and BAK-free travoprost patients. Estimated first-year medical costs were $1,945, $1,803, and $1,730 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis.

Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit the ability to project findings to all glaucoma patients.

Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin analogs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010–2014

Schmier JK, Hulme-Lowe CK, Covert DW, Lau EC

Clinical Ophthalmology 2016, 10:2121-2127

Published Date: 26 October 2016

Estimated hospital costs associated with preventable health care-associated infections if health care antiseptic products were unavailable

Schmier JK, Hulme-Lowe CK, Semenova S, Klenk JA, DeLeo PC, Sedlak R, Carlson PA

ClinicoEconomics and Outcomes Research 2016, 8:197-205

Published Date: 13 May 2016

Treatment costs of cystoid macular edema among patients following cataract surgery

Schmier JK, Covert DW, Hulme-Lowe CK, Mullins A, Mahlis EM

Clinical Ophthalmology 2016, 10:477-483

Published Date: 16 March 2016

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs

Schmier JK, Hulme-Lowe CK, Covert DW

Clinical Ophthalmology 2014, 8:1097-1104

Published Date: 10 June 2014

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs

Jordana K Schmier, Edmund C Lau, David W Covert

Clinical Ophthalmology 2010, 4:1137-1143

Published Date: 29 September 2010

First-year treatment costs among new initiators of topical prostaglandin analogs

Jordana K Schmier, David W Covert, Alan L Robin

Clinical Ophthalmology 2009, 3:637-644

Published Date: 16 November 2009

Characteristics of respondents with glaucoma and dry eye in a national panel survey

Jordana K Schmier, David W Covert

Clinical Ophthalmology 2009, 3:645-650

Published Date: 13 November 2009

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010